
InflaRx to Report First Quarter 2025 Results on May 7, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …